Standardization of α-L-iduronidase enzyme assay with Michaelis-Menten kinetics.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Molecular Genetics and Metabolism

• Publication date

  2014-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ymgme.2013.11.009PMID 24332804PMCID PMC4014300
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulatory science and product quality perspectives for lysosomal storage diseases

  2013cited by this paper
• Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration.

  2012cited by this paper
• Increased Longevity and Metabolic Correction Following Syngeneic Bone Marrow Transplantation in a Murine Model of Mucopolysaccharidosis Type I

  2011cited by this paper
• Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I.

  2011cited by this paper
• A Self-inactivating γ-Retroviral Vector Reduces Manifestations of Mucopolysaccharidosis I in Mice.

  2010cited by this paper
• Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model.

  2010cited by this paper
• Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system.

  2009cited by this paper
• Improved retroviral vector design results in sustained expression after adult gene therapy in mucopolysaccharidosis I mice

  2008cited by this paper
• Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon‐mediated gene delivery: implications for non‐viral gene therapy of mucopolysaccharidoses

  2007cited by this paper
• Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation.

  2007cited by this paper
• Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy.

  2007cited by this paper
• Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice.

  2005cited by this paper
• Gene Therapy for a Mucopolysaccharidosis Type I Murine Model with Lentiviral-IDUA Vector

  2005cited by this paper
• Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene.

  2004cited by this paper
• Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow.

  2003cited by this paper
• A nonpathologic allele (IW) for low alpha-L-iduronidase enzyme activity vis-a-vis prenatal diagnosis of Hurler syndrome.

  1987cited by this paper
• Bone marrow transplantation for Hurler syndrome: assessment of metabolic correction.

  1986cited by this paper
• A fluorometric assay using 4-methylumbelliferyl alpha-L-iduronide for the estimation of alpha-L-iduronidase activity and the detection of Hurler and Scheie syndromes.

  1979cited by this paper
• A fluorometric assay using 4-methylumbelliferyl α-l-iduronide for the estimation of α-l-iduronidase activity and the detection of Hurler and Scheie syndromes

  1979influential reference
• The Determination of Enzyme Dissociation Constants

  1934cited by this paper

• An engineered U7 small nuclear RNA scaffold greatly increases ADAR-mediated programmable RNA base editing

  2025cites this paper
• Antibodies to recombinant human alpha-L-iduronidase prevent disease correction in cortical bone in MPS I mice

  2025cites this paper
• Synergistic effects of resveratrol and enzyme replacement therapy in the Mucopolysaccharidosis type I.

  2024cites this paper
• Ready-to-use iPSC-derived microglia progenitors for the treatment of CNS disease in mouse models of neuropathic mucopolysaccharidoses

  2024cites this paper
• Inhibitors of dermatan sulfate epimerase 1 decreased accumulation of glycosaminoglycans in mucopolysaccharidosis type I fibroblasts

  2024cites this paper
• Synthesis of Os@ZIF-8 nanocomposites with enhanced peroxidase-like activity for detection of Hg2+

  2024cites this paper
• Identification of a novel fusion Iduronidase with improved activity in the cardiovascular system

  2022cites this paper
• Brain and visceral gene editing of mucopolysaccharidosis I mice by nasal delivery of the CRISPR/Cas9 system

  2022cites this paper
• Synthesis of Uronic Acid 1‐Azasugars as Putative Inhibitors of α‐Iduronidase, β‐Glucuronidase and Heparanase **

  2022cites this paper
• In utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease

  2021cites this paper
• Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement

  2021cites this paper
• Inhibition of iduronic acid biosynthesis by ebselen reduces glycosaminoglycan accumulation in mucopolysaccharidosis type I fibroblasts

  2021cites this paper
• Biochemical diagnosis of mucopolysaccharidosis in a Mexican reference center

  2020cites this paper
• Emerging Approaches for Fluorescence-Based Newborn Screening of Mucopolysaccharidoses

  2020cites this paper
• A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I.

  2020cites this paper
• ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome

  2018cites this paper
• Brassica rapa hairy root based expression system leads to the production of highly homogenous and reproducible profiles of recombinant human alpha‐L‐iduronidase

  2018cites this paper
• RTB lectin-mediated delivery of lysosomal α-l-iduronidase mitigates disease manifestations systemically including the central nervous system.

  2017cites this paper
• Mutagenesis of Human Alpha-Galactosidase A for the Treatment of Fabry Disease

  2017cites this paper
• Elements of lentiviral vector design toward gene therapy for treating mucopolysaccharidosis I

  2016cites this paper
• DETERMINATION OF ENZYME KINETIC PARAMETERS ON SAGO STARCH HYDROLYSIS BY LINEARIZED GRAPHICAL METHODS

  2014cites this paper
• CHARACTERIZING METABOLIC ACTIVITY OF FISH LIVER CHARACTERIZING METABOLIC ACTIVITY OF FISH LIVER MICROSOMES TOWARDS FLUOXETINE IN FOUR FISH SPECIES MICROSOMES TOWARDS FLUOXETINE IN FOUR FISH SPECIES USING MICHAELIS-MENTEN ENZYME KINETICS USING MICHAELIS-MENTEN ENZYME KINETICS

  year unknowncites this paper